Literature DB >> 3742067

Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma.

C Klintenberg, O Stål, B Nordenskjöld, A Wallgren, S Arvidsson, L Skoog.   

Abstract

The predictive value of tumor cell estrogen receptor (ER) content, DNA ploidy, proliferative index (PI) and lymph node involvement was examined in 210 women operated on for primary breast cancer in 1979. At a minimum follow-up of 60 months the highest relapse free survival was observed in patients whose tumours had ER greater than 0.30 fmole/micrograms DNA (ER rich) and PI less than 5% (PI low). Subclassification of tumors in euploid and aneuploid groups gave no prognostic information. When examined by axillary node status (no nodal involvement - involved nodes) both ER and PI contributed prognostic information. Multivariate analysis using Cox proportional hazards model showed that nodal involvement was the strongest predictor of recurrence (p = 0.0007). However, ER and PI contributed significant independent prognostic information (p = 0.048 and p = 0.038), respectively.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3742067

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: correlation and relative prognostic influence.

Authors:  T Hatschek; O Gröntoft; G Fagerberg; O Stål; S Sullivan; J Carstensen; B Nordenskjöld
Journal:  Breast Cancer Res Treat       Date:  1990-05       Impact factor: 4.872

2.  Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas.

Authors:  S B Ewers; R Attewell; B Baldetorp; A Borg; E Långström; D Killander
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

3.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

Authors:  A von Rosen; L E Rutqvist; J Carstensen; A Fallenius; L Skoog; G Auer
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

4.  Characterization of four in vitro established canine mammary carcinoma and one atypical benign mixed tumor cell lines.

Authors:  E Hellmén
Journal:  In Vitro Cell Dev Biol       Date:  1992-05

Review 5.  DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

Authors:  D W Hedley; G M Clark; C J Cornelisse; D Killander; T Kute; D Merkel
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

6.  The DNA labelling index: a prognostic factor in node-negative breast cancer.

Authors:  M Héry; J Gioanni; C M Lalanne; M Namer; A Courdi
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

7.  S-phase determination of immunoselected cytokeratin-containing breast cancer cells improves the prediction of recurrence.

Authors:  S Wingren; O Stål; J Carstensen; X F Sun; B Nordenskjöld
Journal:  Breast Cancer Res Treat       Date:  1994-02       Impact factor: 4.872

8.  Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.

Authors:  Jill K Schinkel; Shelia Hoar Zahm; Ismail Jatoi; Katherine A McGlynn; Christopher Gallagher; Catherine Schairer; Craig D Shriver; Kangmin Zhu
Journal:  Cancer Causes Control       Date:  2014-05-17       Impact factor: 2.506

9.  Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma.

Authors:  G Gasparini; S Dal Fior; F Pozza; P Bevilacqua
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

10.  Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.

Authors:  S Wingren; O Stål; B Nordenskjöld
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.